Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Bre...( - Zometa when added to hormone ther...),Health

- Zometa when added to hormone therapy, following surgery, significantly

reduced the risk of cancer returning or death by 36% beyond clinical

benefits achieved with hormone therapy alone(1)

- Findings may allow clinicians to improve standard of care for premenopausal women diagnosed with hormone-sensitive, early-stage breast

cancer - These are the first data from a large clinical program exploring the direct anticancer effect of Zometa in breast, lung and prostate cancer

EAST HANOVER, N.J., May 31 /PRNewswire/ -- New data presented today showed that Zometa(R) (zoledronic acid) offered a significant anticancer benefit for premenopausal women with hormone-sensitive, early-stage breast cancer. The study found that Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novartis/33472/

Investigators from the Austrian Breast & Colorectal Cancer Study Group (ABCSG) announced the findings during a plenary presentation today at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, USA.

"This study is the first large-scale trial to demonstrate the significant antitumor benefit of zoledronic acid," said lead investigator Michael Gnant, M.D., of the Medical University of Vienna. "These new findings may allow oncologists to further improve the standard of care for premenopausal women with hormone-sensitive breast cancer."

According to the World Health Organization (WHO), each year approximately 500,000 women die worldwide because their breast cancer has returned or spread(2). Moreover, the incidence of breast cancer has been rising in recent
'/>"/>